Action ITCI INTRA-CELLULAR THERAPIES, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Intra-Cellular Therapies, Inc.

Actions

ITCI

US46116X1019

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 26/04/2024 		Varia. 5j. Varia. 1 janv.
73,26 USD +1,57 % Graphique intraday de Intra-Cellular Therapies, Inc. +1,23 % +2,29 %
23/04 INTRA-CELLULAR THERAPIES, INC. : Canaccord Genuity reste à l'achat ZM
23/04 INTRA-CELLULAR THERAPIES, INC. : Needham & Co. à l'achat ZM

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Intra-Cellular Therapies Prices Public Offering of Common Stock - April 18, 2024
Intra-Cellular Therapies Prices $500 Million Stock Offering
Intra-Cellular Therapies Prices Public Offering of Common Stock
Intra-Cellular Therapies Launches $500 Million Public Offering of Stock; Shares Edge Lower in Late Trade
UnitedHealth Group, Morgan Stanley rise; PNC Financial, Live Nation fall, Tuesday, 4/16/2024
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
Sector Update: Health Care Stocks Higher Late Afternoon
Top Midday Gainers
US Stocks Lacking Direction Prior to Powell Remarks, Investors Looking for Signs of Future Rate Cuts by Federal Reserve
Intra-Cellular Therapies Stock Jumps After Major Depressive Disorder Treatment Study Shows Positive Results
Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
Intra-Cellular Therapies CFO Hineline Retiring, Promotes Halstead to President
Intra-Cellular Therapies Announces Executive Appointments and Leadership Changes
Intra-Cellular Therapies, Inc. Announces Executive Changes
Intra-Cellular Therapies, Inc. Announces Retirement of Larry Hineline as Chief Financial Officer
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences
Intra-Cellular Therapies Insider Sold Shares Worth $1,458,650, According to a Recent SEC Filing
Intra-Cellular Therapies Insider Sold Shares Worth $1,808,253, According to a Recent SEC Filing
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action ITCI
  4. Actualités Intra-Cellular Therapies, Inc.
  5. Autres langues